Learn More
SummaryOne hundred and sixteen patients with locally advanced or metastatic breast cancer were randomized to receive CMF (cyclophosphamide 600 mg m–2 day 1 and 8 i.v., 5-fluorouracil 600 mg m–2 day 1(More)